Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20173806 | 0.89 | OPRK1 (0.45) | HDAC6HDAC8OPRK1OPRM1PTGER1 | |
| SCHEMBL21882600 | 0.84 | WNT1 (0.46) | HDAC6HDAC8OPRM1PRMT5SMN1; SMN2 | |
| SCHEMBL20173805 | 0.83 | HDAC6 (0.44) | HDAC6HDAC8OPRK1OPRM1PTGER1 | |
| SCHEMBL25873240 | 0.80 | POLB (0.50) | HDAC6HDAC8PTGER1HTTHSP90AA1 | |
| SCHEMBL20173800 | 0.79 | HDAC6 (0.46) | HDAC6HDAC8OPRK1OPRM1PTGER1 | |
| SCHEMBL20173798 | 0.77 | HDAC6 (0.44) | HDAC6HDAC8PTGER1 | |
| SCHEMBL20173799 | 0.77 | PTGS1 (0.44) | HDAC6HDAC8OPRK1OPRM1PTGER1 | |
| SCHEMBL20173793 | 0.77 | ALDH1A1 (0.51) | HDAC6HDAC8PTGER1MAPT | |
| SCHEMBL3879495 | 0.76 | ACACB (0.54) | HDAC6HDAC8PTGER1SMN1; SMN2 | |
| SCHEMBL13791770 | 0.76 | HDAC6 (0.42) | HDAC6HDAC8PTGER1HSP90AA1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | NR1H4, FXR1, SLC10A1 | HDAC6 597/4885HDAC8 1166/4885OPRK1 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.